These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2406863)

  • 1. Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori.
    McNulty CA
    Rev Infect Dis; 1990; 12 Suppl 1():S94-8. PubMed ID: 2406863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.
    McNulty CA; Gearty JC; Crump B; Davis M; Donovan IA; Melikian V; Lister DM; Wise R
    Br Med J (Clin Res Ed); 1986 Sep; 293(6548):645-9. PubMed ID: 3092967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bismuth subsalicylate treatment in chronic Campylobacter pylori-associated erosive gastritis].
    Malfertheiner P; Stanescu A; Baczako K; Vanek E; Bode G; Ditschuneit H
    Dtsch Med Wochenschr; 1988 Jun; 113(23):923-9. PubMed ID: 3378501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin.
    Drumm B; Sherman P; Chiasson D; Karmali M; Cutz E
    J Pediatr; 1988 Nov; 113(5):908-12. PubMed ID: 3183851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of bismuth subsalicylate on the histologic gastritis seen with Campylobacter pylori: a placebo-controlled, randomized study.
    Lanza FL; Skoglund ML; Rack MF; Yardley JH
    Am J Gastroenterol; 1989 Sep; 84(9):1060-4. PubMed ID: 2773899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer.
    Eberhardt R; Kasper G
    Rev Infect Dis; 1990; 12 Suppl 1():S115-9. PubMed ID: 2406852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of Campylobacter-associated gastritis.
    McNulty CA
    Am J Gastroenterol; 1987 Mar; 82(3):245-7. PubMed ID: 3493685
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathogenicity of Campylobacter pylori--a causative factor in gastritis?
    McNulty CA
    Scand J Gastroenterol Suppl; 1989; 160():3-6. PubMed ID: 2683021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bismuth subsalicylate suppression of Helicobacter pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial.
    Marshall BJ; Valenzuela JE; McCallum RW; Dooley CP; Guerrant RL; Cohen H; Frierson HF; Field LG; Jerdack GR; Mitra S
    Dig Dis Sci; 1993 Sep; 38(9):1674-80. PubMed ID: 8359080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Campylobacter pylori does not alter gastric acid secretion.
    Montbriand JR; Appelman HD; Cotner EK; Nostrant TT; Elta GH
    Am J Gastroenterol; 1989 Dec; 84(12):1513-6. PubMed ID: 2596452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
    Rösch W
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing the eradication of Helicobacter pylori with triple therapy.
    Graham DY; Lew GM; Malaty HM; Evans DG; Evans DJ; Klein PD; Alpert LC; Genta RM
    Gastroenterology; 1992 Feb; 102(2):493-6. PubMed ID: 1732120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).
    Morris A; Brown P; Ali MR; Lane M; Palmer R
    N Z Med J; 1988 Oct; 101(856 Pt 1):651-4. PubMed ID: 3054641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with Campylobacter pylori in western Kentucky.
    Kraus JW; Morello PJ
    J Ky Med Assoc; 1989 Sep; 87(9):448-50. PubMed ID: 2794757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dose-effect studies with bismuth salts for the elimination of Campylobacter pylori].
    Menge H; Hofmann J; Gregor M
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():44-6. PubMed ID: 3318192
    [No Abstract]   [Full Text] [Related]  

  • 16. [Epidemiology and therapy of Campylobacter pylori infection].
    Wagner S; Freise J; Bär W; Fritsch S; Schmidt FW
    Dtsch Med Wochenschr; 1989 Mar; 114(11):407-13. PubMed ID: 2707124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate.
    Loffeld RJ; Potters HV; Stobberingh E; Flendrig JA; van Spreeuwel JP; Arends JW
    Gut; 1989 Sep; 30(9):1206-12. PubMed ID: 2680795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperplastic gastric polyps associated with persistent Helicobacter pylori infection and active gastritis.
    Veereman Wauters G; Ferrell L; Ostroff JW; Heyman MB
    Am J Gastroenterol; 1990 Oct; 85(10):1395-7. PubMed ID: 2220735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
    Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Campylobacter pylori in patients with dyspeptic symptoms and endoscopic evidence of erosion(s).
    Elta GH; Murphy R; Behler EM; Barnett JL; Nostrant TT; Kern S; Appelman H
    Am J Gastroenterol; 1989 Jun; 84(6):643-6. PubMed ID: 2729235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.